A Phase 4 interventional study of Docetaxel and Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 9 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 141st largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2015, is one of 5 in phase 4, and was the 220th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 10 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 132nd largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2015, is one of 11 in phase 4, and was the 146th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor receptor 2 (HER2)-positive advanced (locally recurrent, unresectable, or metastatic) breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab
Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Also known as: Perjeta®
Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Also known as: Herceptin®, Herclon®
Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant
The number of participants with serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 serious adverse event categories) were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)
The number of participants with serious adverse events was counted by the initial and most extreme levels of severity of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of serious adverse events of the same severity were only counted once per severity category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Serious Adverse Events Related to Docetaxel
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Serious Adverse Events Related to Pertuzumab
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Serious Adverse Events Related to Trastuzumab
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug
The number of participants with serious adverse events was counted by the type of action taken with the study drug (docetaxel, pertuzumab, and trastuzumab) in response to the adverse event in the three following categories: infusion reduced, temporarily interrupted, or permanently discontinued. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events that required the same action to be taken with the study drug were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Serious Adverse Events by Event Outcome
The number of participants with serious adverse events was counted by the event outcome in the six following categories: fatal, recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, or unknown. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events with the same outcome were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events
The number of participants with hematological laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events
The number of participants with serum chemistry laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events
The number of participants with coagulation laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death
The number of participants who died due to a serious adverse event was counted by the cause of death.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant
The number of participants with non-serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 non-serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 non-serious adverse event categories) were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03
The number of participants with non-serious adverse events was counted by the severity level of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of non-serious adverse events of the same severity were only counted once per severity category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Non-Serious Adverse Events Related to Docetaxel
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Non-Serious Adverse Events Related to Pertuzumab
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Non-Serious Adverse Events Related to Trastuzumab
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab
The number of participants with non-serious adverse events was counted by the type of action taken with docetaxel and/or trastuzumab in response to the adverse event in the three following categories: no adjustment, dosage modified/interrupted, and discontinued. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab
The number of participants with non-serious adverse events was counted by the type of action taken with pertuzumab in response to the adverse event in the three following categories: no action taken, infusion slow down, infusion interrupted, and appropriate medical therapies administered. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Non-Serious Adverse Events by Event Outcome
The number of participants with non-serious adverse events was counted by the event outcome in the four following categories: resolved with no sequelae, resolved with sequelae, unresolved, or death. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events with the same outcome were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)
The number of participants with non-serious adverse events was counted according to whether the event was considered a treatment emergent adverse event (TEAE), which is defined as an adverse event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. Participants with multiple occurrences of non-serious adverse events were only counted once per category.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events
The number of participants with hematological laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events
The number of participants with serum chemistry laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events
The number of participants with coagulation laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
Time frame: From Baseline until end of study (up to approximately 3 years)
Number of Participants With Congestive Heart Failure
Time frame: From Baseline until end of study (up to approximately 3 years)
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time
Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF of ≥50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution.
Time frame: Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)
Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time
Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF greater than or equal to (≥)50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF ≥45%; 'Abnormal but not clinically significant' was defined as LVEF \<45% but not clinically significant in the investigator's judgment; 'Abnormal and clinically significant' was defined as LVEF \<45% and clinically significant in the investigator's judgment.
Time frame: Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)
Number of Participants With Adverse Events Leading to Treatment Discontinuation
The number of participants with any adverse event (serious or non-serious) that led to treatment discontinuation during the study was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one adverse event that led to treatment discontinuation may have been reported per participant.
Time frame: From Baseline until end of study (up to approximately 3 years)
Overall Response Rate
The overall response rate (ORR) was defined as the percentage of participants with best overall response of Complete Response (CR) or Partial Response (PR), confirmed by repeat assessment no less than 4 weeks after the response criteria were first met, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Participants who either had not achieved CR or PR or were without a post-baseline tumor assessment were to be considered non-responders. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator. The 95% confidence intervals were calculated using Clopper-Pearson methodology.
Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Number of Participants by Best Overall Response
The best overall response was defined as the best response, out of all the documented responses over the course of the entire study period, using RECIST v1.1. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator.
Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Number of Participants With Disease Progression or Death or Who Were Censored for Progression-Free Survival Analysis
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Median Duration of Progression-Free Survival
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died, or were lost to follow up at the time of the analysis, were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Probability of Participants Remaining Event-Free in Progression-Free Survival From 2 to 32 Months
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed, died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
Time frame: Months 2, 3, 5, 6, 7, 8, 9, 11, 13, 15, 16, 17, 18, 19, 23, 24, 25, 27, 29, and 32
Number of Participants Who Died or Were Censored for Overall Survival Analysis
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
Time frame: From Baseline up to death from any cause (up to approximately 3 years)
Median Duration of Overall Survival
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
Time frame: From Baseline up to death from any cause (up to approximately 3 years)
Probability of Participants Remaining Alive in Overall Survival From 3 to 34 Months
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
Time frame: Months 3, 9, 13, 14, 15, 18, 19, 20, 24, 25, 27, 32, 33, and 34
| Milestone | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Started | 52 |
| Received at least one dose of study drug | 52 |
| Completed | 13 |
| Not completed | 39 |
| Withdrew: Death | 14 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Disease progression | 10 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Medical condition | 1 |
The number of participants with serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 serious adverse event categories) were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| ≥1 Serious Adverse Event | 31 |
| 1 Serious Adverse Event | 17 |
| >1 Serious Adverse Events | 14 |
| 0 Serious Adverse Events | 21 |
The number of participants with serious adverse events was counted by the initial and most extreme levels of severity of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of serious adverse events of the same severity were only counted once per severity category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Initial Severity - Grade 1 | 1 |
| Initial Severity - Grade 2 | 4 |
| Initial Severity - Grade 3 | 15 |
| Initial Severity - Grade 4 | 7 |
| Initial Severity - Grade 5 | 14 |
| Most Extreme Severity - Grade 1 | 1 |
| Most Extreme Severity - Grade 2 | 3 |
| Most Extreme Severity - Grade 3 | 16 |
| Most Extreme Severity - Grade 4 | 7 |
| Most Extreme Severity - Grade 5 | 15 |
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any Serious AEs Related to Docetaxel | 15 |
| Diarrhoea | 5 |
| Left ventricular dysfunction | 2 |
| Fatigue | 2 |
| Sinus tachycardia | 1 |
| Abdominal pain | 1 |
| Febrile neutropenia | 1 |
| Enteritis | 1 |
| Salivary hypersecretion | 1 |
| Stomatitis | 1 |
| Vomiting | 1 |
| Pyrexia | 1 |
| Device related sepsis | 1 |
| Septic shock | 1 |
| Infusion related reaction | 1 |
| Rash | 1 |
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any Serious AEs Related to Pertuzumab | 13 |
| Diarrhoea | 4 |
| Ejection fraction decreased | 3 |
| Left ventricular dysfunction | 2 |
| Sinus tachycardia | 1 |
| Abdominal pain | 1 |
| Enteritis | 1 |
| Stomatitis | 1 |
| Fatigue | 1 |
| Pyrexia | 1 |
| Gastroenteritis | 1 |
| Dyspnoea | 1 |
| Rash | 1 |
| Shock | 1 |
The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any Serious AEs Related to Trastuzumab | 10 |
| Ejection fraction decreased | 3 |
| Left ventricular dysfunction | 2 |
| Diarrhoea | 2 |
| Enteritis | 1 |
| Fatigue | 1 |
| Pyrexia | 1 |
| Sinus tachycardia | 1 |
| Rash | 1 |
| Shock | 1 |
The number of participants with serious adverse events was counted by the type of action taken with the study drug (docetaxel, pertuzumab, and trastuzumab) in response to the adverse event in the three following categories: infusion reduced, temporarily interrupted, or permanently discontinued. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events that required the same action to be taken with the study drug were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Infusion of Docetaxel Reduced | 0 |
| Infusion of Docetaxel Temporarily Interrupted | 1 |
| Infusion of Docetaxel Permanently Discontinued | 1 |
| Infusion of Pertuzumab Reduced | 0 |
| Infusion of Pertuzumab Temporarily Interrupted | 3 |
| Infusion of Pertuzumab Permanently Discontinued | 4 |
| Infusion of Trastuzumab Reduced | 0 |
| Infusion of Trastuzumab Temporarily Interrupted | 3 |
| Infusion of Trastuzumab Permanently Discontinued | 5 |
The number of participants with serious adverse events was counted by the event outcome in the six following categories: fatal, recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, or unknown. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events with the same outcome were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Fatal | 15 |
| Recovered / Resolved | 18 |
| Recovered / Resolved with Sequelae | 1 |
| Recovering / Resolving | 3 |
| Not Recovered / Not Resolved | 2 |
| Unknown | 0 |
The number of participants with hematological laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events | 2 |
The number of participants with serum chemistry laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events | 0 |
The number of participants with coagulation laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events | 1 |
The number of participants who died due to a serious adverse event was counted by the cause of death.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Disease progression | 10 |
| Sepsis and disease progression | 1 |
| Dyspnoea | 1 |
| Septic shock | 1 |
| Shock | 1 |
| Unknown cause | 1 |
The number of participants with non-serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 non-serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 non-serious adverse event categories) were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| ≥1 Non-Serious Adverse Event | 47 |
| 1 Non-Serious Adverse Event | 11 |
| >1 Non-Serious Adverse Events | 36 |
| 0 Non-Serious Adverse Events | 5 |
The number of participants with non-serious adverse events was counted by the severity level of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of non-serious adverse events of the same severity were only counted once per severity category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Grade 1 | 38 |
| Grade 2 | 34 |
| Grade 3 | 12 |
| Grade 4 | 1 |
| Grade 5 | 0 |
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any Non-Serious AEs Related to Docetaxel | 30 |
| Diarrhoea | 12 |
| Anaemia | 7 |
| Stomatitis | 6 |
| Leukopenia | 4 |
| Alopecia | 4 |
| Vomiting | 4 |
| Pain | 4 |
| Fatigue | 4 |
| Oedema peripheral | 3 |
| Skin ulcer | 2 |
| Hypokalaemia | 2 |
| Lacrimation increased | 2 |
| Asthenia | 2 |
| Pyrexia | 2 |
| Paraesthesia | 2 |
| Peripheral sensory neuropathy | 2 |
| Dry skin | 2 |
| Rash | 2 |
| Skin exfoliation | 2 |
| Muscular weakness | 1 |
| Febrile neutropenia | 1 |
| Thrombocytopenia | 1 |
| Sinus tachycardia | 1 |
| Abdominal pain | 1 |
| Anal fistula | 1 |
| Anorectal discomfort | 1 |
| Constipation | 1 |
| Frequent bowel movements | 1 |
| Gastritis | 1 |
| Haemorrhoidal haemorrhage | 1 |
| Hyperchlorhydria | 1 |
| Oral discomfort | 1 |
| Chest pain | 1 |
| Peripheral swelling | 1 |
| Genital herpes | 1 |
| Pyoderma | 1 |
| Skin infection | 1 |
| Urinary tract infection | 1 |
| Liver function test abnormal | 1 |
| Decreased appetite | 1 |
| Hypomagnesaemia | 1 |
| Hypophosphataemia | 1 |
| Joint swelling | 1 |
| Limb discomfort | 1 |
| Pain in extremity | 1 |
| Burning sensation | 1 |
| Neuropathy peripheral | 1 |
| Productive cough | 1 |
| Dermatitis acneiform | 1 |
| Rash maculo-papular | 1 |
| Seborrhoeic dermatitis | 1 |
| Skin hypertrophy | 1 |
| Stevens-Johnson syndrome | 1 |
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any Non-Serious AEs Related to Pertuzumab | 20 |
| Diarrhoea | 10 |
| Stomatitis | 5 |
| Pain | 3 |
| Ejection fraction decreased | 3 |
| Rash | 3 |
| Lacrimation increased | 2 |
| Chills | 2 |
| Nasal dryness | 2 |
| Dry skin | 2 |
| Oedema peripheral | 1 |
| Skin ulcer | 1 |
| Left ventricular dysfunction | 1 |
| Sinus tachycardia | 1 |
| Abdominal discomfort | 1 |
| Generalised oedema | 1 |
| Pyrexia | 1 |
| Hypokalaemia | 1 |
| Hypomagnesaemia | 1 |
| Myalgia | 1 |
| Burning sensation | 1 |
| Neuropathy peripheral | 1 |
| Breast discomfort | 1 |
| Productive cough | 1 |
| Dermatitis acneiform | 1 |
| Onycholysis | 1 |
| Rash maculo-papular | 1 |
The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Number of Participants With Non-Serious Adverse Events Related to Trastuzumab | 0 |
The number of participants with non-serious adverse events was counted by the type of action taken with docetaxel and/or trastuzumab in response to the adverse event in the three following categories: no adjustment, dosage modified/interrupted, and discontinued. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| No Adjustment | 45 |
| Dosage Modified / Interrupted | 9 |
| Discontinued | 7 |
The number of participants with non-serious adverse events was counted by the type of action taken with pertuzumab in response to the adverse event in the three following categories: no action taken, infusion slow down, infusion interrupted, and appropriate medical therapies administered. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| No Action Taken | 47 |
| Infusion Slow Down | 0 |
| Infusion Interrupted | 0 |
| Appropriate Medical Therapies Administered | 0 |
The number of participants with non-serious adverse events was counted by the event outcome in the four following categories: resolved with no sequelae, resolved with sequelae, unresolved, or death. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events with the same outcome were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Resolved with No Sequelae | 42 |
| Resolved with Sequelae | 12 |
| Unresolved | 27 |
| Death | 2 |
The number of participants with non-serious adverse events was counted according to whether the event was considered a treatment emergent adverse event (TEAE), which is defined as an adverse event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. Participants with multiple occurrences of non-serious adverse events were only counted once per category.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| TEAEs | 47 |
| Non-TEAEs | 3 |
The number of participants with hematological laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Anaemia | 8 |
| Leukopenia | 4 |
| Neutropenia | 2 |
| Febrile neutropenia | 1 |
| Iron deficiency | 1 |
| Thrombocytopenia | 1 |
The number of participants with serum chemistry laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Hypomagnesaemia | 4 |
| Hypokalaemia | 2 |
| Hypoalbuminaemia | 1 |
| Hypophosphataemia | 1 |
| Hyperglycaemia | 1 |
| Hyperuricaemia | 1 |
| Liver function test abnormal | 1 |
The number of participants with coagulation laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Thrombocytopenia | 1 |
| Anal haemorrhage | 1 |
| Haemorrhoidal haemorrhage | 1 |
| Rectal haemorrhage | 1 |
| Upper gastrointestinal haemorrhage | 1 |
| Vaginal haemorrhage | 1 |
| Thrombophlebitis | 1 |
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Number of Participants With Congestive Heart Failure | 0 |
Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF of ≥50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution.
| percentage points of LVEF | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Baseline (BL) - Value at Visit | 59.6 ± 3.92 |
| Change from BL at Cycle 3 | -0.7 ± 2.95 |
| Change from BL at Cycle 6 | -0.8 ± 4.09 |
| Change from BL at Cycle 9 | -0.2 ± 4.43 |
| Change from BL at Cycle 12 | 0.2 ± 3.99 |
| Change from BL at Cycle 15 | -0.8 ± 4.33 |
| Change from BL at Cycle 18 | -1.3 ± 4.07 |
| Change from BL at Cycle 21 | -1.8 ± 5.72 |
| Change from BL at Cycle 24 | -0.7 ± 4.03 |
| Change from BL at Cycle 27 | 0.0 ± 2.83 |
| Change from BL at Cycle 30 | -1.3 ± 6.55 |
| Change from BL at Cycle 33 | -0.5 ± 3.21 |
| Change from BL at Cycle 36 | 0.0 ± 2.90 |
| Change from BL at Cycle 39 | -1.3 ± 3.51 |
| Change from BL at Cycle 42 | 1.0 ± 0 |
| Change from BL at Cycle 45 | 0.0 ± 1.41 |
| Change from BL at Cycle 48 | -2.0 ± 2.83 |
| Change from BL at Cycle 51 | -18.0 ± NA |
| Change from BL at Safety Follow-Up | -4.3 ± 12.98 |
| Change from BL at 3 Month Follow-Up | -2.1 ± 4.80 |
| Change from BL at 6 Month Follow-Up | -1.8 ± 4.41 |
| Change from BL at 9 Month Follow-Up | -3.4 ± 6.44 |
| Change from BL at 12 Month Follow-Up | -2.3 ± 4.40 |
| Change from BL at 15 Month Follow-Up | -4.7 ± 5.51 |
| Change from BL at 18 Month Follow-Up | -10.0 ± 7.07 |
| Change from BL at 21 Month Follow-Up | -5.0 ± NA |
| Change from BL at 24 Month Follow-Up | -5.0 ± NA |
Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF greater than or equal to (≥)50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF ≥45%; 'Abnormal but not clinically significant' was defined as LVEF \<45% but not clinically significant in the investigator's judgment; 'Abnormal and clinically significant' was defined as LVEF \<45% and clinically significant in the investigator's judgment.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Baseline — Normal | 50 |
| Baseline — Abnormal But Not Clinically Significant | 2 |
| Baseline — Abnormal and Clinically Significant | 0 |
| Cycle 3 — Normal | 48 |
| Cycle 3 — Abnormal But Not Clinically Significant | 3 |
| Cycle 3 — Abnormal and Clinically Significant | 0 |
| Cycle 6 — Normal | 37 |
| Cycle 6 — Abnormal But Not Clinically Significant | 3 |
| Cycle 6 — Abnormal and Clinically Significant | 0 |
| Cycle 9 — Normal | 24 |
| Cycle 9 — Abnormal But Not Clinically Significant | 1 |
| Cycle 9 — Abnormal and Clinically Significant | 1 |
| Cycle 12 — Normal | 17 |
| Cycle 12 — Abnormal But Not Clinically Significant | 0 |
| Cycle 12 — Abnormal and Clinically Significant | 0 |
| Cycle 15 — Normal | 16 |
| Cycle 15 — Abnormal But Not Clinically Significant | 2 |
| Cycle 15 — Abnormal and Clinically Significant | 0 |
| Cycle 18 — Normal | 11 |
| Cycle 18 — Abnormal But Not Clinically Significant | 2 |
| Cycle 18 — Abnormal and Clinically Significant | 0 |
| Cycle 21 — Normal | 10 |
| Cycle 21 — Abnormal But Not Clinically Significant | 1 |
| Cycle 21 — Abnormal and Clinically Significant | 1 |
| Cycle 24 — Normal | 8 |
| Cycle 24 — Abnormal But Not Clinically Significant | 1 |
| Cycle 24 — Abnormal and Clinically Significant | 0 |
| Cycle 27 — Normal | 5 |
| Cycle 27 — Abnormal But Not Clinically Significant | 2 |
| Cycle 27 — Abnormal and Clinically Significant | 0 |
| Cycle 30 — Normal | 3 |
| Cycle 30 — Abnormal But Not Clinically Significant | 1 |
| Cycle 30 — Abnormal and Clinically Significant | 0 |
| Cycle 33 — Normal | 5 |
| Cycle 33 — Abnormal But Not Clinically Significant | 1 |
| Cycle 33 — Abnormal and Clinically Significant | 0 |
| Cycle 36 — Normal | 5 |
| Cycle 36 — Abnormal But Not Clinically Significant | 1 |
| Cycle 36 — Abnormal and Clinically Significant | 0 |
| Cycle 39 — Normal | 2 |
| Cycle 39 — Abnormal But Not Clinically Significant | 1 |
| Cycle 39 — Abnormal and Clinically Significant | 0 |
| Cycle 42 — Normal | 2 |
| Cycle 42 — Abnormal But Not Clinically Significant | 0 |
| Cycle 42 — Abnormal and Clinically Significant | 0 |
| Cycle 45 — Normal | 2 |
| Cycle 45 — Abnormal But Not Clinically Significant | 0 |
| Cycle 45 — Abnormal and Clinically Significant | 0 |
| Cycle 48 — Normal | 2 |
| Cycle 48 — Abnormal But Not Clinically Significant | 0 |
| Cycle 48 — Abnormal and Clinically Significant | 0 |
| Cycle 51 — Normal | 0 |
| Cycle 51 — Abnormal But Not Clinically Significant | 0 |
| Cycle 51 — Abnormal and Clinically Significant | 1 |
| Safety Follow-Up — Normal | 24 |
| Safety Follow-Up — Abnormal But Not Clinically Significant | 1 |
| Safety Follow-Up — Abnormal and Clinically Significant | 3 |
| 3 Month Follow-Up — Normal | 17 |
| 3 Month Follow-Up — Abnormal But Not Clinically Significant | 3 |
| 3 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 6 Month Follow-Up — Normal | 18 |
| 6 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 6 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 9 Month Follow-Up — Normal | 13 |
| 9 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 9 Month Follow-Up — Abnormal and Clinically Significant | 1 |
| 12 Month Follow-Up — Normal | 10 |
| 12 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 12 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 15 Month Follow-Up — Normal | 3 |
| 15 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 15 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 18 Month Follow-Up — Normal | 2 |
| 18 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 18 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 21 Month Follow-Up — Normal | 1 |
| 21 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 21 Month Follow-Up — Abnormal and Clinically Significant | 0 |
| 24 Month Follow-Up — Normal | 1 |
| 24 Month Follow-Up — Abnormal But Not Clinically Significant | 0 |
| 24 Month Follow-Up — Abnormal and Clinically Significant | 0 |
The number of participants with any adverse event (serious or non-serious) that led to treatment discontinuation during the study was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one adverse event that led to treatment discontinuation may have been reported per participant.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Any AEs Leading to Treatment Discontinuation | 16 |
| Disease progression | 5 |
| Ejection fraction decreased | 3 |
| Headache | 2 |
| Anaemia | 1 |
| Death | 1 |
| Diarrhoea | 1 |
| Dyspnoea | 1 |
| Febrile neutropenia | 1 |
| Infusion related reaction | 1 |
| Sepsis | 1 |
| Septic shock | 1 |
| Shock | 1 |
| Stevens-Johnson syndrome | 1 |
The overall response rate (ORR) was defined as the percentage of participants with best overall response of Complete Response (CR) or Partial Response (PR), confirmed by repeat assessment no less than 4 weeks after the response criteria were first met, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Participants who either had not achieved CR or PR or were without a post-baseline tumor assessment were to be considered non-responders. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator. The 95% confidence intervals were calculated using Clopper-Pearson methodology.
| percentage of participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Responders (ORR) | 82.7 (69.67 to 91.77) |
| Non-Responders | 17.3 (8.23 to 30.33) |
The best overall response was defined as the best response, out of all the documented responses over the course of the entire study period, using RECIST v1.1. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Complete Response (CR) | 0 |
| Partial Response (PR) | 43 |
| Progressive Disease (PD) | 1 |
| Stable Disease (SD) | 6 |
| Unable to Assess | 2 |
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Disease Progression or Death | 32 |
| Censored | 20 |
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died, or were lost to follow up at the time of the analysis, were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
| months | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Median Duration of Progression-Free Survival | 23.0 (13.0 to 29.0) |
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed, died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.
| Percent probability of PFS | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| At 2 Months | 98.08 |
| At 3 Months | 96.15 |
| At 5 Months | 90.27 |
| At 6 Months | 88.30 |
| At 7 Months | 82.42 |
| At 8 Months | 78.49 |
| At 9 Months | 74.57 |
| At 11 Months | 68.52 |
| At 13 Months | 64.49 |
| At 15 Months | 60.33 |
| At 16 Months | 58.10 |
| At 17 Months | 55.86 |
| At 18 Months | 53.63 |
| At 19 Months | 51.30 |
| At 23 Months | 48.96 |
| At 24 Months | 46.63 |
| At 25 Months | 41.72 |
| At 27 Months | 36.16 |
| At 29 Months | 32.87 |
| At 32 Months | 29.59 |
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
| Participants | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Death | 15 |
| Censored | 37 |
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
| months | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Median Duration of Overall Survival | NA (26 to NA) |
Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.
| Percent probability of OS | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| At 3 Months | 96.15 |
| At 9 Months | 88.30 |
| At 13 Months | 88.30 |
| At 14 Months | 88.30 |
| At 15 Months | 88.30 |
| At 18 Months | 83.66 |
| At 19 Months | 83.66 |
| At 20 Months | 83.66 |
| At 24 Months | 81.12 |
| At 25 Months | 81.12 |
| At 27 Months | 68.14 |
| At 32 Months | 68.14 |
| At 33 Months | 64.36 |
| At 34 Months | 64.36 |
Collected over From Baseline until end of study (up to 3 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab in Combination With Trastuzumab and Docetaxel | 15/52 (28.8%) | 31/52 (59.6%) | 47/52 (90.4%) |
| Event | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Disease progressionGeneral disorders | 6/52 |
| DiarrhoeaGastrointestinal disorders | 5/52 |
| DeathGeneral disorders | 3/52 |
| FatigueGeneral disorders | 3/52 |
| Ejection fraction decreasedInvestigations | 3/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/52 |
| Left ventricular dysfunctionCardiac disorders | 2/52 |
| Multiple organ dysfunction syndromeGeneral disorders | 2/52 |
| Septic shockInfections and infestations | 2/52 |
| Event | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| DiarrhoeaGastrointestinal disorders | 17/52 |
| StomatitisGastrointestinal disorders | 8/52 |
| AnaemiaBlood and lymphatic system disorders | 8/52 |
| PyrexiaGeneral disorders | 8/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/52 |
| FatigueGeneral disorders | 8/52 |
| Back painMusculoskeletal and connective tissue disorders | 7/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/52 |
| VomitingGastrointestinal disorders | 6/52 |
| HeadacheNervous system disorders | 6/52 |
| Age, Continuous(years) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Mean | 50.2 ± 9.05 |
| Sex: Female, Male(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Female | 52 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Race: Asian | 52 |
| Ethnicity: Indian Subcontinent | 52 |
| Diagnosis of Metastatic or Locally Recurrent Breast Cancer(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Metastatic | 52 |
| Locally Recurrent | 0 |
| Histological Grade of Breast Cancer(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Well Differentiated | 14 |
| Moderately Differentiated | 16 |
| Poorly Differentiated | 11 |
| Anaplastic | 0 |
| Unknown | 11 |
| Breast Cancer Subtype by Histology(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Ductal | 47 |
| Lobular | 0 |
| Other | 5 |
| Presence or Absence of Ductal Carcinoma In Situ (DCIS)(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| DCIS Present | 22 |
| DCIS Absent | 29 |
| DCIS Assessment Missing | 1 |
| HER2-Positive Breast Cancer Confirmation Method(Participants) | Pertuzumab in Combination With Trastuzumab and Docetaxel |
|---|---|
| Immunohistochemistry (IHC) | 31 |
| In Situ Hybridization (ISH) | 1 |
| Both IHC and ISH | 20 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Sep 2018, 37 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 37 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Pertuzumab